Patient reported outcomes in Friedreich's Ataxia after withdrawal from Idebenone.

This study provides no data to suggest that FRDA patients could correctly determine their treatment assignment over a 2-month period. We hope that this study design will help inform future trials so that patients' experiences of symptoms are more reliably measured. This article is protected by copyright. All rights reserved.